Monday, October 17, 2022

Biocon Biologics inks out-licensing agreement with Yoshindo Inc

Biocon Biologics inks out-licensing agreement with Yoshindo Inc Under the terms of this deal, Japan-based Yoshindo gets exclusive commercialisation rights in Japan for Ustekinumab and Denosumab -- developed and manufactured by Biocon Biologics -- for an addressable market opportunity of USD 700 million, Biocon Biologics said in a statement.

from Moneycontrol Business News https://ift.tt/8o172te
at
Labels: , , ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

LTIMindtree Q4 Preview: Lower pass-through revenue seen impacting growth marginally

A compilation of estimates suggests the company#39;s Q4 FY24 net profit is projected to decline by 2.2 percent quarter on quarter to Rs 1,1...